2-Phenyl-phenylcarbamat | 110030-65-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Phenyl-phenylcarbamat
• 英文别名: Biphenyl carbamate；(2-phenylphenyl) carbamate
• CAS: 110030-65-4
• 化学式: C₁₃H₁₁NO₂
• 分子量: 213.236
• InChiKey: LMTWQLGAIBXCTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Phenyl-phenylcarbamat 在 dirhodium tetraacetate 、 碘苯二乙酸 、 magnesium oxide 作用下， 以 甲苯 为溶剂， 以79%的产率得到7-phenyl-3H-1,3-benzoxazol-2-one
  参考文献：
  名称：

  铑（II）催化的非定向和选择性C（sp 2）–H胺化反应生成苯并恶唑酮

  摘要：

  铑（II）可以通过分子内的氮杂C–H插入反应有效地促进芳基氨基甲酸酯底物的活化和环化，从而生成苯并恶唑啉酮。对底物范围的研究表明，该反应在更不稳定的o -C（sp 3）-H键上进行了选择性芳族C（sp 2）-H胺化反应。反向二次KIE的观察结果（P H / P D = 0.42±0.03）表明，芳族亲电取代机理参与了芳基CH酰胺化反应。

  DOI：

  10.1021/acscatal.6b02237

文献信息

• [EN] CORTICOSTEROID-BETA-AGONIST-MUSCARINIC ANTAGONIST COMPOUNDS FOR USE IN THERAPY<br/>[FR] COMPOSÉS DE TYPE CORTICOSTÉROÏDE-BÊTA-AGONISTE-ANTAGONISTE MUSCARINIQUE POUR APPLICATIONS THÉRAPEUTIQUES
  申请人：GILEAD SCIENCES INC

  公开号：WO2011081937A1

  公开（公告）日：2011-07-07

  The instant invention relates to new chemical entities which comprise corticosteroids, phosphorylated β-agonists and muscarinic (M3) antagonists for use in therapy and compositions comprising and processes for preparing the same.

  这项即时发明涉及新的化学实体，包括皮质类固醇、磷酸化β-激动剂和毒蕈碱（M3）拮抗剂，用于治疗以及包含这些化学实体的组合物和制备它们的方法。
• Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
  申请人：Colson Pierre-Jean

  公开号：US20070249675A1

  公开（公告）日：2007-10-25

  This invention relates to compounds of formula I: wherein R 1 and R 2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

  本发明涉及式I的化合物：其中R1和R2如规范中定义，或其药用可接受的盐或溶剂或立体异构体。该发明还涉及包含这类化合物的药物组合物和配方，用于制备这类化合物的过程和中间体，以及使用这类化合物治疗肺部疾病，如慢性阻塞性肺病和哮喘等方法。
• Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
  申请人：——

  公开号：US20040209860A1

  公开（公告）日：2004-10-21

  This invention provides biphenyl derivatives containing (i) a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; (ii) a substituted 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; and a divalent hydrocarbon group, where each group is further defined and optionally substituted as described in the specification. The biphenyl derivatives of the invention possess both &bgr; 2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

  该发明提供了含有以下结构的联苯衍生物：(i)一个(biphenyl-2-yl)oxycarbonylamino-或(biphenyl-2-yl)aminocarbonylamino取代的(2-7C)氮杂环烷基或(5-10C)氮杂双环烷基；(ii)一个取代的2-(4-羟基苯基)-2-羟乙基氨基基团；以及一个二价碳氢基团，其中每个基团进一步在说明书中描述并可选地取代。该发明的联苯衍生物具有β2肾上腺素受体激动剂和毒蕈碱受体拮抗剂活性，因此，这种联苯衍生物对于治疗肺部疾病，如慢性阻塞性肺疾病和哮喘，是有用的。
• Modulation of anxiety through blockade of anandamide hydrolysis
  申请人：The Regents of the University of California

  公开号：US20040127518A1

  公开（公告）日：2004-07-01

  Fatty acid amide hydrolase inhibitors of the Formula: 1 are provided wherein X is NH, CH 2 , O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R 1 and R 2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R 1 and R 2 is absent, and that if Z is N, optionally R 1 and R 2 may optionally be taken together to form a substituted or unsubstituted N-heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they are each attached. Pharmaceutical compositions comprising the compounds of Formula I and methods of using them to inhibit FAAH and/or treat appetite disorders, glaucoma, pain, insomnia, and neurological and psychological disorders including anxiety disorders, epilepsy, and depression are provided.

  本发明提供了公式1中X为NH，CH2，O或S；Q为O或S；Z为O或N；R为从取代或未取代芳基；取代或未取代联苯基；取代或未取代萘基；取代或未取代苯基；取代或未取代三苯基基；取代或未取代环烷基，杂环芳基或烷基中选择的芳香基；R1和R2分别独立地选择从H，取代或未取代烷基，取代或未取代杂环烷基和取代或未取代苯基，取代或未取代联苯基，取代或未取代芳基和取代或未取代杂环芳基的群中选择；但是如果Z为O，则R1和R2中的一个不存在，如果Z为N，则R1和R2可以选择性地一起形成取代或未取代的N-杂环或取代或未取代的杂环芳基，与它们各自连接的N原子。本发明还提供了包括公式I中化合物的制药组合物以及使用它们来抑制FAAH和/或治疗食欲障碍，青光眼，疼痛，失眠和神经心理障碍，包括焦虑症，癫痫和抑郁症的方法。
• DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
  申请人：Colson Pierre-Jean

  公开号：US20100137603A1

  公开（公告）日：2010-06-03

  This invention relates to compounds of formula I: wherein R 1 and R 2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

  本发明涉及I式化合物： 其中R1和R2如本说明书所定义，或其药学上可接受的盐、溶剂或立体异构体。本发明还涉及包括这种化合物的药物组合物和制备这种化合物的中间体和过程，以及使用这种化合物的方法，例如用于治疗肺部疾病，如慢性阻塞性肺疾病和哮喘。